Renaissance Technologies LLC Purchases Shares of 143,093 Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Renaissance Technologies LLC purchased a new stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 143,093 shares of the company’s stock, valued at approximately $4,271,000. Renaissance Technologies LLC owned 0.23% of Kymera Therapeutics as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of KYMR. Charles Schwab Investment Management Inc. raised its holdings in Kymera Therapeutics by 1.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 306,692 shares of the company’s stock valued at $7,808,000 after acquiring an additional 4,951 shares during the period. Norges Bank bought a new stake in Kymera Therapeutics during the fourth quarter valued at about $12,834,000. UBS Group AG raised its holdings in Kymera Therapeutics by 84.6% during the fourth quarter. UBS Group AG now owns 300,463 shares of the company’s stock valued at $7,650,000 after acquiring an additional 137,704 shares during the period. TD Asset Management Inc raised its holdings in Kymera Therapeutics by 1.3% during the fourth quarter. TD Asset Management Inc now owns 186,482 shares of the company’s stock valued at $4,748,000 after acquiring an additional 2,400 shares during the period. Finally, Campbell & CO Investment Adviser LLC bought a new stake in shares of Kymera Therapeutics in the fourth quarter worth about $792,000.

Insider Buying and Selling

In other news, Director Bruce Booth sold 453,960 shares of the firm’s stock in a transaction dated Tuesday, July 9th. The stock was sold at an average price of $38.21, for a total transaction of $17,345,811.60. Following the sale, the director now directly owns 723,246 shares in the company, valued at approximately $27,635,229.66. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, Director Bruce Booth sold 453,960 shares of Kymera Therapeutics stock in a transaction that occurred on Tuesday, July 9th. The shares were sold at an average price of $38.21, for a total transaction of $17,345,811.60. Following the sale, the director now owns 723,246 shares of the company’s stock, valued at approximately $27,635,229.66. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Pamela Esposito sold 13,500 shares of the business’s stock in a transaction that occurred on Tuesday, September 17th. The shares were sold at an average price of $48.28, for a total value of $651,780.00. The disclosure for this sale can be found here. Insiders sold 495,605 shares of company stock worth $19,303,364 in the last 90 days. Insiders own 15.82% of the company’s stock.

Kymera Therapeutics Trading Down 1.6 %

Shares of NASDAQ KYMR opened at $48.69 on Friday. The stock has a market capitalization of $2.99 billion, a PE ratio of -19.40 and a beta of 2.22. The stock’s fifty day simple moving average is $45.79 and its two-hundred day simple moving average is $39.35. Kymera Therapeutics, Inc. has a 12-month low of $9.60 and a 12-month high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.58) EPS for the quarter, beating the consensus estimate of ($0.68) by $0.10. The firm had revenue of $25.60 million during the quarter, compared to analyst estimates of $12.55 million. Kymera Therapeutics had a negative return on equity of 28.88% and a negative net margin of 178.27%. The business’s revenue for the quarter was up 55.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.67) EPS. On average, equities analysts predict that Kymera Therapeutics, Inc. will post -2.87 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. Oppenheimer boosted their target price on Kymera Therapeutics from $52.00 to $56.00 and gave the stock an “outperform” rating in a research report on Friday. Morgan Stanley upped their price objective on Kymera Therapeutics from $34.00 to $45.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 14th. HC Wainwright restated a “buy” rating and set a $46.00 price objective on shares of Kymera Therapeutics in a research report on Monday, June 17th. Wolfe Research upgraded Kymera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $65.00 price objective on the stock in a research report on Monday, August 26th. Finally, B. Riley upped their price objective on Kymera Therapeutics from $31.00 to $36.00 and gave the company a “neutral” rating in a research report on Tuesday, July 9th. Four investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $49.00.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.